6.53  0.15 (2.35%)		04-19 16:00
Open: 6.31 High: 6.8 Volume: 469,122		Pre. Close: 6.38 Low: 6.18 Market Cap: 417(M)

Short term
Mid term
Targets	6-month :	9.53	1-year :	10.85
Resists	First :	8.15	Second :	9.28
Pivot price	7.2
Supports	First :	6.33	Second :	5.26
MAs	MA(5) :	6.98	MA(20) :	7.33
	MA(100) :	6.73	MA(250) :	4.88
MACD	MACD :	-0.6	Signal :	-0.6
%K %D	K(14,3) :	19.5	D(3) :	25.8
RSI	RSI(14): 33.6
52-week	High :	13.68	Low :	2.18

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ LRMR ] has closed below the lower bollinger band by 15.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 58.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	7.01 - 7.06	7.06 - 7.1
Low:	6.22 - 6.28	6.28 - 6.32
Close:	6.3 - 6.39	6.39 - 6.45

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Fri, 12 Apr 2024
Short Interest in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Expands By 95.7% - MarketBeat

Thu, 04 Apr 2024
Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) Price Target at $18.50 - MarketBeat

Thu, 14 Mar 2024
LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023 - InvestorPlace

Fri, 16 Feb 2024
Larimar Therapeutics Secures $161.8M from Public Offering - TipRanks.com - TipRanks

Wed, 14 Feb 2024
Larimar Therapeutics Ends Sales Agreement with Guggenheim Securities - TipRanks.com - TipRanks

Wed, 14 Feb 2024
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	64 (M)
Shares Float	33 (M)
Held by Insiders	1.3 (%)
Held by Institutions	83.5 (%)
Shares Short	3,190 (K)
Shares Short P.Month	507 (K)

EPS	-0.84
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.86
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-23.5 %
Return on Equity (ttm)	-38.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.65
Qtrly Earnings Growth	0 %
Operating Cash Flow	-33 (M)
Levered Free Cash Flow	-21 (M)

PE Ratio	-7.6
PEG Ratio	0
Price to Book value	3.43
Price to Sales	0
Price to Cash Flow	-12.17

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.